Anzeige
Mehr »
Freitag, 04.07.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
207 Leser
Artikel bewerten:
(0)

OBI Pharma Announces Poster Presentations at 2020 ASCO Virtual Annual Meeting for Adagloxad Simolenin, OBI-999 and OBI-3424

Poster Presentations to highlight the ongoing clinical studies targeting Globo H and AKR1C3 antigens in different tumor types

TAIPEI, Taiwan, May 20, 2020 /PRNewswire/ -- OBI Pharma, Inc. (TPEx: 4174), a leader in Glycosphingolipid Immuno-Oncology therapeutics targeting the Globo Series antigens (Globo H and SSEA-4) and chemotherapeutics targeting AKR1C3, today announced that data highlighting the ongoing clinical studies targeting Globo H and AKR1C3 antigen in different tumor types will be presented at the American Society of Clinical Oncology (ASCO) ASCO20 Virtual Scientific Program from May 29-31, 2020.

These studies will be presented by the lead investigators of OBI Pharma's first-in-class anti-Globo H cancer vaccine (Adagloxad Simolenin) and Antibody Drug Conjugate (OBI-999), and AKR1C3 targeting prodrug (OBI-3424).

"Based upon our anti-Globo H and AKR1C3 targeted approaches in cancers of high unmet needs, OBI Pharma is proud to have posters on the progress of our trials presented at ASCO20 for our first-in-class therapeutics Adagloxad Simolenin, OBI-999, and OBI-3424. We look forward to providing future updates of our studies, which we believe could offer potential therapeutic benefits to patients suffering from cancer," stated Tillman Pearce, MD, Chief Medical Officer at OBI Pharma.

Abstract: TPS599 / Poster: 91
Title: Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adagloxad simolenin (OBI-822) and OBI-821 treatment in patients with early-stage triple-negative breast cancer (TNBC) at high risk for recurrence.
Presenter: Hope S. Rugo, MD, FASCO University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Session Title: Breast Cancer-Local/Regional/Adjuvant
Session Date and Time: Friday, May 29, 2020. 8:00 a.m. -- 11:00 a.m. Eastern Time
https://meetinglibrary.asco.org/record/191690/abstract

Abstract: TPS3657 / Poster: 387
Title: A phase I/II, open-label, dose-escalation, and cohort-expansion study evaluating the safety, pharmacokinetics, and therapeutic activity of OBI-999 in patients with advanced solid tumors.
Session Title: Developmental Therapeutics-Molecularly Targeted Agents and Tumor Biology
Presenter: Apostolia Maria Tsimberidou, MD, Ph.D, The University of Texas MD Anderson Cancer Center, Houston, TX
Session Date and Time: Friday, May 29, 2020. 8:00 a.m. -- 11:00 a.m. Eastern Time
https://meetinglibrary.asco.org/record/191854/abstract

Abstract: TPS3658 / Poster: 388
Title: A first-in-man phase I/II study of OBI-3424, an AKR1C3-selective bis-alkylating agent prodrug, in subjects with advanced cancer, including hepatocellular carcinoma (HCC) and castrate-resistant prostate cancer (CRPC).
Session Title: Developmental Therapeutics-Molecularly Targeted Agents and Tumor Biology
Presenter: Apostolia Maria Tsimberidou, MD, Ph.D, The University of Texas MD Anderson Cancer Center, Houston, TX
Session Date and Time: Friday, May 29, 2020. 8:00 a.m. -- 11:00 a.m. Eastern Time
https://meetinglibrary.asco.org/record/191750/abstract

The above poster presentations will be available online at www.obipharma.com on May 29, 2020.

About OBI Pharma

OBI Pharma, Inc., is a Taiwan biopharmaceutical company that was established in 2002. Its mission is to develop and license novel therapeutic agents for unmet medical needs against cancer targets such as Globo Series (including Globo H, SSEA-3 and SSEA-4), AKR1C3, and other promising targets.

The company's novel first-in-class immuno-oncology portfolio against Globo H includes: Adagloxad Simolenin (formerly OBI-822) and OBI 833, a Globo H active immunotherapy vaccine; OBI-888 (Globo H mAb) and OBI-999 (Globo H ADC). The company's novel first-in-class AKR1C3 targeted therapy is OBI-3424 (small-molecule prodrug) that selectively releases a potent DNA alkylating agent in the presence of the aldo-keto reductase 1C3 (AKR1C3) enzyme. Additional information can be found at www.obipharma.com.

Forward-Looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about future clinical trials, results and the timing of such trials and results. Such risk factors are identified and discussed from time to time in OBI Pharma's reports and presentations, including OBI Pharma's filings with the Taiwan Securities and Futures Bureau.

COMPANY CONTACT:
Kevin Poulos
OBI Pharma USA, Inc.
1.619.537.7698 Ext. 102
kpoulos@obipharmausa.com

© 2020 PR Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.